Dosing Regimens of Bispecific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies
The present invention is directed to a dosing regimen for administering a CD 123×CDS bispecific diabody to patients with a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The present invention is also directed to a dosing regimen for administering a CD...
Saved in:
Main Authors | , , , , , |
---|---|
Format | Patent |
Language | English |
Published |
07.07.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention is directed to a dosing regimen for administering a CD 123×CDS bispecific diabody to patients with a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The present invention is also directed to a dosing regimen for administering a CD 123×CDS bispecific diabody in combination with a molecule capable of binding PD-1 or a natural ligand of PD-1 (a "PD-1 or PD-1 ligand binding molecule") to patients with a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The invention particularly concerns the use of such regimens for administering the sequence-optimized CD 123×CDS bispecific diabody, "DART-A," which is capable of simultaneous binding to CD 123 and CDS. |
---|---|
Bibliography: | Application Number: US202017601787 |